⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
AI Exposure Analysis
Healthcare · Small Cap · Disruption threat: LOW
Recursion is a techbio company where AI and machine learning are not ancillary but foundational to its entire drug discovery platform, using large proprietary biological datasets and AI models to identify therapeutic candidates at scale. Its 2025-2026 pipeline and Recursion OS platform continue to deepen AI integration, though revenue remains largely partnership- and milestone-driven rather than direct AI product sales.
Recursion Pharmaceuticals (RXRX) operates at the intersection of biology and artificial intelligence, deploying machine learning as the structural foundation of its drug discovery engine rather than as a supplementary tool. Its Recursion OS platform leverages large-scale proprietary biological datasets, high-content imaging, and phenomics data to identify therapeutic candidates at scale, positioning the company firmly within the techbio category. Product AI Integration (92/100), Internal AI Use (90/100), and R&D AI Investment (88/100) are the primary score drivers, reflecting how deeply AI is embedded across operations. AI Infrastructure (82/100) further supports the platform's scalability, including biological foundation model development. The weaker dimension is Revenue from AI (45/100), consistent with the company's partnership- and milestone-driven model with counterparties such as Roche and Bayer, rather than direct commercialization of AI products. The overall score of 78/100 reflects genuine AI integration tempered by limited revenue conversion. The low disruption threat assessment is appropriate. Recursion is not vulnerable to AI-driven displacement; rather, it is the disruptor, using proprietary data advantages and platform scale to compete against traditional drug discovery approaches. The key risk remains the long pathway from AI-identified candidates to approved therapeutics. Revenue dependency on partnerships introduces concentration risk, and clinical-stage execution will ultimately determine whether the AI platform translates into durable shareholder value.
Full interactive analysis at RankVis.io